Trevena Management

Management Kriterienprüfungen 2/4

Trevena's CEO ist Carrie Bourdow , ernannt in Oct 2018, hat eine Amtszeit von 5.67 Jahren. Die jährliche Gesamtvergütung beträgt $1.66M , bestehend aus 40.9% Gehalt und 59.1% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.51% der Aktien des Unternehmens, im Wert von $36.59K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 5.7 Jahre bzw. 9.9 Jahre.

Wichtige Informationen

Carrie Bourdow

Geschäftsführender

US$1.7m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	40.9%
Amtszeit als Geschäftsführer	5.7yrs
Eigentum des Geschäftsführers	0.5%
Durchschnittliche Amtszeit des Managements	5.7yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	9.9yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Carrie Bourdow im Vergleich zu den Einnahmen von Trevena verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	-US$40m
Dec 31 2023	US$2m	US$682k	-US$40m
Sep 30 2023	n/a	n/a	-US$31m
Jun 30 2023	n/a	n/a	-US$38m
Mar 31 2023	n/a	n/a	-US$45m
Dec 31 2022	US$1m	US$656k	-US$54m
Sep 30 2022	n/a	n/a	-US$61m
Jun 30 2022	n/a	n/a	-US$59m
Mar 31 2022	n/a	n/a	-US$58m
Dec 31 2021	US$2m	US$637k	-US$52m
Sep 30 2021	n/a	n/a	-US$50m
Jun 30 2021	n/a	n/a	-US$41m
Mar 31 2021	n/a	n/a	-US$33m
Dec 31 2020	US$3m	US$613k	-US$29m
Sep 30 2020	n/a	n/a	-US$24m
Jun 30 2020	n/a	n/a	-US$27m
Mar 31 2020	n/a	n/a	-US$25m
Dec 31 2019	US$2m	US$563k	-US$25m
Sep 30 2019	n/a	n/a	-US$26m
Jun 30 2019	n/a	n/a	-US$22m
Mar 31 2019	n/a	n/a	-US$27m
Dec 31 2018	US$2m	US$418k	-US$31m
Sep 30 2018	n/a	n/a	-US$38m
Jun 30 2018	n/a	n/a	-US$49m
Mar 31 2018	n/a	n/a	-US$60m
Dec 31 2017	US$1m	US$341k	-US$72m

Vergütung im Vergleich zum Markt: CarrieDie Gesamtvergütung ($USD1.66M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD673.68K).

Entschädigung vs. Einkommen: CarrieDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Carrie Bourdow (61 yo)

5.7yrs

Amtszeit

US$1,664,855

Vergütung

Ms. Carrie L. Bourdow has been Chief Executive Officer, President and Director at Trevena, Inc. since October 01, 2018 and serves as its Chairman since November 09, 2023. Ms. Bourdow served as an Executive...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Carrie Bourdow	President	5.7yrs	US$1.66m	0.51% $ 20.0k
Barry Shin	Executive VP	5yrs	US$1.01m	0.21% $ 8.4k
Mark Demitrack	Senior VP & Chief Medical Officer	6.1yrs	US$1.03m	0.20% $ 7.9k
Howard Rockman	Scientific Founder	no data	keine Daten	keine Daten
Joel Solomon	VP, General Counsel	no data	keine Daten	keine Daten
Michael Catalano	Vice President of Marketing	6.3yrs	keine Daten	keine Daten
Robert Yoder	Senior VP	5.5yrs	US$689.16k	0.12% $ 4.6k

5.7yrs

Durchschnittliche Betriebszugehörigkeit

59.5yo

Durchschnittliches Alter

Erfahrenes Management: TRVNDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (5.7 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Carrie Bourdow	President	5.7yrs	US$1.66m	0.51% $ 20.0k
Howard Rockman	Scientific Founder	no data	keine Daten	keine Daten
William Schmidt	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Jason Nunn	Independent Director	10.9yrs	US$76.11k	0.00093% $ 36.7
John LaMattina	Member of the Scientific Advisory Board	15.4yrs	keine Daten	keine Daten
Robert Lefkowitz	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Robert R. Ruffolo	Member of the Scientific Advisory Board	15.4yrs	keine Daten	keine Daten
Mark H. Corrigan	Independent Director	less than a year	US$55.87k	0% $ 0
Anne Phillips	Independent Director	10.4yrs	US$76.11k	0% $ 0
Scott Braunstein	Lead Independent Director	5.8yrs	US$70.11k	0% $ 0
Barbara Yanni	Independent Director	9.9yrs	US$76.58k	0.00027% $ 10.6
Marvin Johnson	Independent Director	3.3yrs	US$61.11k	0% $ 0

9.9yrs

Durchschnittliche Betriebszugehörigkeit

70yo

Durchschnittliches Alter

Erfahrener Vorstand: TRVNDie Vorstandsmitglieder gelten als erfahren (9.9 Jahre durchschnittliche Amtszeit).

Trevena Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Trevena, Inc., Annual General Meeting, Jun 13, 2024

Trevena, Inc. Promotion of Barry Shin to the Position of Executive Vice President and Chief Operating Officer

Trevena, Inc. Announces Board Changes

Trevena, Inc. Announces Retirement of Michael Dougherty as A Member of the Board of Directors and as A Member of the Audit Committee, Effective as of September 14, 2023

Trevena, Inc. Appoints Mark Corrigan to Board of Directors

Insufficient new directors

Recent updates

Trevena, Inc. Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism of Analgesic Effect in Chronic Neuropathic Pain Model and Demonstrating Statistically Significant Anti-Seizure Activity in Epilepsy Models

First quarter 2024 earnings released: US$0.36 loss per share (vs US$0.81 loss in 1Q 2023)

Nasdaq Hearings Panel Grants Trevena an Extension Until August 28, 2024 to Regain Compliance with the Nasdaq Continued Listing Requirements, Including the Minimum Bid Price Requirement and Equity Standard Requirement

Trevena, Inc., Annual General Meeting, Jun 13, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues miss analyst expectations

No longer forecast to breakeven

New major risk - Market cap size

Trevena, Inc. Promotion of Barry Shin to the Position of Executive Vice President and Chief Operating Officer

Trevena, Inc. announced that it expects to receive $1.945934 million in funding

Trevena, Inc. announced that it expects to receive $1.945934 million in funding

Trevena, Inc. announced that it expects to receive $1.945934 million in funding

Trevena, Inc. Announces Acceptance of Abstract Examining the Use of Olinvyk in Patients with Acute Burn Injuries

New major risk - Revenue and earnings growth

Consensus EPS estimates fall by 28%, revenue upgraded

Trevena, Inc. Announces Board Changes

Trevena, Inc. to Report Q3, 2023 Results on Nov 14, 2023

New major risk - Revenue and earnings growth

Trevena, Inc. Announces Completion of Initial Analysis of Olinvyk Continuous Respiratory Monitoring Data from Volition Study

Trevena, Inc. Announces Retirement of Michael Dougherty as A Member of the Board of Directors and as A Member of the Audit Committee, Effective as of September 14, 2023

Trevena, Inc. Announces Preliminary TRV045 Data from Two Proof-Of-Concept Studies Evaluating S1pr Mechanism of Action and CNS Target Engagement

Trevena Receives Non-Compliance Notice From Nasdaq Stock Market

Consensus revenue estimates increase by 725%

New major risk - Market cap size

Trevena, Inc. Appoints Mark Corrigan to Board of Directors

Trevena, Inc. Announces New Topline OLINVYK Data Highlighting Reduced Cost Per Admission from Artemis Real-World Outcomes Study

New major risk - Market cap size

Trevena Regains Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5550(a)(2)

Trevena, Inc. to Report Q1, 2023 Results on May 15, 2023

Price target decreased by 39% to US$17.00

Trevena Announces Publication of OLINVYK Respiratory Physiology Study in ANESTHESIOLOGY

Trevena, Inc. Enrolls First Subject in TRV045 Proof-of-Concept Trial Evaluating S1PR Mechanism of Action and Target Engagement

Trevena Regains Compliance with Nasdaq Listing Requirements

Price target decreased to US$28.67

Insufficient new directors

Trevena Announces Completion of Phase 1 Study for Trv045, Novel S1p Receptor Modulator

Trevena, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Trevena Announces OLINVYK Poster Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Trevena Q2 2022 Earnings Preview

Trevena, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Trevena Announces Positive Topline OLINVYK Cognitive Function Data and Provides General Business Update

Trevena slides on $2M preferred stock offering

Trevena (NASDAQ:TRVN) Will Have To Spend Its Cash Wisely

Trevena Gets an Additional 180 Days to Get Listing Compliance

Consensus revenue estimates fall by 36%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Trevena, Inc., Annual General Meeting, Jun 09, 2022

Insufficient new directors

Trevena, Inc. Receives Notice to Cease Enrollment for TRV027 as Part of the ACTIV-4 Host Tissue Platform

Trevena, Inc. Announces Results from Pfound D Sedation, Respiratory Depression, Coma, and Death May Result from E Concomitant Use of Olinvyk

Consensus forecasts updated

Trevena, Inc. to Report Q4, 2021 Results on Mar 31, 2022

Is Trevena (NASDAQ:TRVN) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$4.67

Insufficient new directors

Trevena, Inc. Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical

Trevena, Inc. Announces Advancement of TRV045 Into Clinical Development for Diabetic Neuropathic Pain

Trevena Offers An Enticing Risk-Reward At These Prices

Trevena Announces Wake Forest Baptist Health Joining OLINVYK® Clinical Outcomes Study

Trevena: Remaining Patient After A Disappointing Q2 Earnings

Trevena Announces Publication of OLINVYK® Health Economic Model in Journal of Comparative Effectiveness Research

Trevena Announces NIH Has Resumed Recruiting Patients in Proof-of-Concept Study for TRV734 in Opioid Use Disorder

Trevena announces resumption of NIH-run trial for TRV734 in opioid use disorder

Trevena, Inc. Announces Presentation of OLINVYK® Respiratory Safety Data in High-Risk Patients at the 46th Annual ASRA Meeting

Trevena's OLINVYK Provides One Of The Most Compelling Growth Profiles

Trevena Investor Presentation - Slideshow

Trevena, Inc. Announces TRV027 Selected by NIH-Funded ACTIV Initiative for COVID-19 Trial